|drug2331||MenACWY single dose Wiki||1.00|
|drug887||ChAdOx1 nCoV-19 single dose Wiki||1.00|
|drug2332||MenACWY two dose Wiki||1.00|
There is one clinical trial.
COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed to have a high potential for transmission to close contacts on 20 January 2020 by the National Health Commission of China and it was announced as a pandemic by the WHO on 11 March 2020. There is currently no clinically proven specific antiviral agent available for SARS-CoV-2 infection. Supportive treatment, including oxygen therapy, conservation fluid management, and broad-spectrum antibiotics to cover secondary bacterial infection, remains the most important management strategy. Interestingly, sofosbuvir has recently been proposed as an antiviral for the SARS-CoV-2 based on the similarity between the replication mechanisms of the HCV and the coronaviruses. Aim of our study is to assess the safety and efficacy of of the addition of HCV treatment to the standard regimen for the treatment of patients according to MOHP protocol.
Description: All PCR for COVID must be negativeMeasure: rate of virological cure by Rt -PCR for COVID -19using the triple therapy as compared to standard treatment Time: for every case must be done after 2 weeks from the start of treatment.
Description: clinical status as assessed by earlier resolution of pneumonia in the intervention arm when compared to the control groupMeasure: resolution of pneumonia BY high resolution Computed tomography Time: Computed tomography must be done after 2 weeks to detect resolution of pneumonia
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports